Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1966 1
1967 2
1970 1
1974 3
1977 1
1978 3
1979 4
1980 1
1981 1
1982 3
1983 2
1984 6
1985 6
1986 11
1987 14
1988 9
1989 7
1990 16
1991 15
1992 18
1993 19
1994 20
1995 22
1996 22
1997 20
1998 25
1999 37
2000 40
2001 35
2002 50
2003 30
2004 34
2005 49
2006 60
2007 68
2008 64
2009 55
2010 70
2011 68
2012 66
2013 54
2014 52
2015 65
2016 52
2017 61
2018 56
2019 45
2020 67
2021 76
2022 71
2023 47
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

1,477 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS Collaborators. Furuta S, et al. Among authors: kita y. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615. JAMA. 2021. PMID: 34061144 Free PMC article. Clinical Trial.
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, Tanaka T, Goto H, Nakano Y, Iida N, Arai K, Yamashita T, Mizukoshi E, Nakamura H, Kaneko S, Takamura T. Takeshita Y, et al. Among authors: kita y. Diabetes Care. 2022 Sep 1;45(9):2064-2075. doi: 10.2337/dc21-2049. Diabetes Care. 2022. PMID: 35894933 Free PMC article. Clinical Trial.
Paraurachal paraganglioma.
Tsuruta M, Goto T, Kono J, Kita Y, Masui K, Sano T, Fujimoto M, Sawada A, Akamatsu S, Kobayashi T. Tsuruta M, et al. Among authors: kita y. IJU Case Rep. 2022 May 31;5(5):358-361. doi: 10.1002/iju5.12488. eCollection 2022 Sep. IJU Case Rep. 2022. PMID: 36090947 Free PMC article.
[Rheumatoid arthritis].
Kita Y. Kita Y. Nihon Rinsho. 2015 Sep;73 Suppl 7:649-54. Nihon Rinsho. 2015. PMID: 26480772 Free article. Japanese. No abstract available.
Cytosolic phospholipase A2 and lysophospholipid acyltransferases.
Kita Y, Shindou H, Shimizu T. Kita Y, et al. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):838-845. doi: 10.1016/j.bbalip.2018.08.006. Epub 2018 Aug 9. Biochim Biophys Acta Mol Cell Biol Lipids. 2019. PMID: 30905348 Review.
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS collaborators. Furuta S, et al. Among authors: kita y. Ann Rheum Dis. 2024 Jan 2;83(1):96-102. doi: 10.1136/ard-2023-224343. Ann Rheum Dis. 2024. PMID: 37734880 Clinical Trial.
Self-organization, quality control, and preclinical studies of human iPSC-derived retinal sheets for tissue-transplantation therapy.
Watari K, Yamasaki S, Tu HY, Shikamura M, Kamei T, Adachi H, Tochitani T, Kita Y, Nakamura A, Ueyama K, Ono K, Morinaga C, Matsuyama T, Sho J, Nakamura M, Fujiwara M, Hori Y, Tanabe A, Hirai R, Terai O, Ohno O, Ohara H, Hayama T, Ikeda A, Nukaya D, Matsushita K, Takahashi M, Kishino A, Kimura T, Kawamata S, Mandai M, Kuwahara A. Watari K, et al. Among authors: kita y. Commun Biol. 2023 Feb 10;6(1):164. doi: 10.1038/s42003-023-04543-5. Commun Biol. 2023. PMID: 36765170 Free PMC article.
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK, Kim WY. Okato A, et al. Among authors: kita y. J Clin Invest. 2024 Jan 16;134(2):e169241. doi: 10.1172/JCI169241. J Clin Invest. 2024. PMID: 38226620 Free PMC article.
1,477 results